Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
 
Taj Logo
taj Products
 
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
 

a healthy life

 
HOME >> PRODUCTS >> Taj Products >> Dectrovir-N
Taj  ALL Products View Products According to Category

Composition

Lamivudine ............................................................150 mg
Zidovudine USP ............................................................300 mg
Nevirapine ............................................................200 mg

drugs+hiv

Indications
Dectrovir-N is indicated for the treatment of HIV infection, once patients have been stabilized on the maintenance regimen of nevirapine 200 mg bd, and have demonstrated adequate tolerability to nevirapine.

Description
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time.

Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.

Side Effects
In controlled clinical trials, the most common Nevirapine side effect was rash, which in 7.6% of subjects was considered severe. Increases in the liver enzymes occurred in 5-10% of subjects compared with 2-5% in controls.

CONTRAINDICATIONS
Nevirapine is contraindicated in patients with clinically significant hypersensitivity to any of the components contained in the tablet or the oral suspension.

Drug Interaction
Nevirapine is principally metabolized by the liver via the cytochrome P450 isoenzymes, 3A4 and 2B6. Nevirapine is known to be an inducer of these enzymes. As a result, drugs that are metabolized by these enzyme systems may have lower than expected plasma levels when coadministered with nevirapine.

Dosage
Adults: 1 tablet twice daily or as per the physician’s advice.

Presentations
30 tablets

 

 

 

 


Note : This product information is intended only for residents of the India. Taj Pharmaceuticals Limited,  medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).


Nevirapine is a Non-Nucleoside Reverse Transcriptase Inhibitor
 

   Dectrovir-N ® Taj Products
Product Gallery
PDF Download
Doc Download
MSDS Download
COA Download
 Prescription Products (Rx)
 
men-women-hiv-and-aids









 

 

 

 

 

 

 

 

 

 

 

 


              
 Print page   Send by mail

 

 

 



 

   
   
PRODUCTS
 
 
   
   
   
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market
    AFRICA
  ASIA PACIFIC
  EUROPE
  MIDDLE EAST
  THAILAND
  BANGLADESH
  NORTH AMERICA
  SOUTH AMERICA
  RUSSIA
  NEWZELAND
  UNITED KINGDOM
 

` stop aids

 

 

 

 

 
 www.tajpharma.com

   

 

About Taj

Company

Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors

Countries

Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement